Acute Myelogenous Lymphoma (AML)

First (CR1)/Second (CR2) Remission

- BMT330 Phase II Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT
  PI: Muffy
  Sponsor: Stanford

- BMT302 Phase II Ibrutinib Maintenance After Reduced-Intensity Conditioning &Allogeneic HCT in Acute Leukemia
  PI: Rezvani Stanford

Advanced Disease

- Matched Related or Unrelated Donor

- Matched Related Donor

First (CR1) or Higher Remission

- Matched Related or Unrelated Donor

- Matched Related Donor

BMT236 Phase III Tacrolimus/Methotrexate vs Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in PBSCT
  PI: Rezvani
  BMTCTN

BMT340 Phase III MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells PI: Meyer NIH

BMT338 Phase I Donor Grafts Derived From OrcaGraft w/GVHD Prophylaxis in MA-aloHCT in Hematologic Malignancies
  PI: Meyer Orca Biosystems

BMT339 CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS&AL
  PI: Lowsky Pending

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu